Business Context and Reporting Period
Mira Pharmaceuticals, Inc. filed a Form 8-K reporting an event dated January 15, 2024. The company is incorporated in Florida, trades on the Nasdaq Capital Market under the symbol MIRA, and identifies as an emerging growth company.
Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Christos Nicholoudis, Esq. resigned from the company’s Board of Directors and from his role as part-time General Counsel effective January 15, 2024.
- The filing states that the resignation did not involve any disagreement with the company, management, or the Board regarding operations, policies, or practices.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, outlook, risk updates, contingencies, or unusual financial items. It does not disclose a successor director or replacement General Counsel.
Investor Verification Items
- Confirm the company’s current Board composition following Mr. Nicholoudis’s resignation.
- Determine whether the company has appointed a replacement General Counsel or disclosed changes in legal oversight.
- Review subsequent filings for additional explanations, appointments, or effects on company operations.